‘Next Cochlear’ stock surges after heart device breakthrough
Tess BennettTechnology reporter
Shares in an ASX-listed medical technology firm backed by investors including Bill Ferris and Mark Carnegie have surged 10.5 per cent on Monday after it revealed positive clinical trial results, which clear the way for US Food and Drug Administration approval for its tiny cardiovascular device.
EBR Systems chief executive John McCutcheon says the trials are the most significant development for the company so far.
Subscribe to gift this article
Gift 5 articles to anyone you choose each month when you subscribe.
Subscribe nowAlready a subscriber?
Introducing your Newsfeed
Follow the topics, people and companies that matter to you.
Find out moreRead More
Latest In Technology
Fetching latest articles